Varian, Still River Systems to collaborate on interface development
Varian Medical Systems and Still River Systems have formed an agreement to develop an interface between Varian's Aria oncology information system and Still River's Monarch250 proton beam radiotherapy system.
Aria is an oncology information system that manages radiotherapy treatments for cancer clinical processes, according to Corey Zankowski, Varian's senior director for product management. "In addition to providing a complete electronic medical record for oncology, Aria is exceptional at recording and verifying the numerous treatment parameters and instruction sets required for complex radiotherapy treatments,” he added.
Still River of Littleton, Mass., will provide technical assistance to the Palo Alto, Calif.-based Varian engineers, who will develop the interface to allow ‘record and verify’ functionality across the two systems.
“We are developing the Monarch250 proton therapy system to support existing clinical processes. The Monarch250 Aria interface will allow cancer centers to integrate proton therapy within their existing radiation therapy practices,” added Skip Rosenthal, PhD, vice president of clinical systems at Still River.
Any new Aria interface that facilitates ‘record and verify’ functions with additional radiotherapy delivery technologies are subject to 510(k) clearance by the FDA, and would need such clearance prior to clinical deployment, Varian said.
Aria is an oncology information system that manages radiotherapy treatments for cancer clinical processes, according to Corey Zankowski, Varian's senior director for product management. "In addition to providing a complete electronic medical record for oncology, Aria is exceptional at recording and verifying the numerous treatment parameters and instruction sets required for complex radiotherapy treatments,” he added.
Still River of Littleton, Mass., will provide technical assistance to the Palo Alto, Calif.-based Varian engineers, who will develop the interface to allow ‘record and verify’ functionality across the two systems.
“We are developing the Monarch250 proton therapy system to support existing clinical processes. The Monarch250 Aria interface will allow cancer centers to integrate proton therapy within their existing radiation therapy practices,” added Skip Rosenthal, PhD, vice president of clinical systems at Still River.
Any new Aria interface that facilitates ‘record and verify’ functions with additional radiotherapy delivery technologies are subject to 510(k) clearance by the FDA, and would need such clearance prior to clinical deployment, Varian said.